Leap Therapeutics Reports Increased Q1 Losses

Leap Therapeutics ( (LPTX) ) has released its Q1 earnings. Here is a breakdown of the information Leap Therapeutics presented to its investors.

Leap Therapeutics, Inc. is a biopharmaceutical company focused on developing novel biomarker-targeted antibody therapies for cancer treatment, with its lead program being sirexatamab (DKN-01), a monoclonal antibody targeting DKK1. In its latest earnings report, Leap Therapeutics reported a net loss of $15.4 million for the first quarter of 2025, compared to a net loss of $13.8 million in the same period last year. The company’s operating expenses increased to $15.9 million, primarily due to higher research and development costs. Leap Therapeutics’ cash and cash equivalents decreased to $32.7 million from $47.2 million at the end of 2024, reflecting the company’s ongoing investment in its development programs. Despite the financial challenges, Leap Therapeutics remains committed to advancing its clinical trials and exploring additional funding opportunities to support its operations. The management continues to focus on the development and potential commercialization of its lead program, sirexatamab, while seeking strategic partnerships to enhance its financial position.